Skip to main content
Luoxin Pharmaceuticals Group Stock Co., Ltd. logo

Luoxin Pharmaceuticals Group Stock Co., Ltd. — Investor Relations & Filings

Ticker · 002793 ISIN · CNE1000026S7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,599 across all filing types
Latest filing 2026-05-20 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 002793

About Luoxin Pharmaceuticals Group Stock Co., Ltd.

https://www.luoxin.cn

Luoxin Pharmaceuticals Group Stock Co., Ltd. focuses on the research, development, manufacturing, and distribution of diverse medicinal products. The company specializes in therapeutic areas including digestive health, respiratory medicine, anti-infectives, and oncology. Its portfolio includes various formulations such as injections, tablets, and capsules, with a notable emphasis on proton pump inhibitors and respiratory treatments. Luoxin operates a vertically integrated model, producing both active pharmaceutical ingredients (APIs) and finished dosage forms. The organization emphasizes innovation through dedicated R&D facilities to develop high-quality healthcare solutions. Its operations are supported by a comprehensive supply chain and manufacturing infrastructure designed to adhere to international quality standards, serving broad market segments with a focus on clinical efficacy and patient accessibility.

Recent filings

Filing Released Lang Actions
关于控股子公司的产品注射用阿奇霉素情况说明的公告
Legal Proceedings Report Classification · 91% confidence The document is a voluntary company announcement detailing an administrative penalty imposed by the Shandong Provincial Drug Supervision Administration on the company’s subsidiary, including background of the event, penalty details, investigation findings and remediation measures. This is a regulatory action rather than a financial report or board change, fitting the definition for Legal Proceedings Report (LTR): updates on significant lawsuits or regulatory actions involving the company.
2026-05-20 Chinese
关于转让控股子公司股权的进展公告
M&A Activity Classification · 87% confidence The document is a corporate announcement by a listed company regarding the progress of transferring its 70% controlling equity stake in a subsidiary, detailing payment schedules, performance commitment fulfilment, and next steps. This describes a divestiture transaction (asset sale) rather than financial results, regulatory filings, or board changes. Under our taxonomy, disposal of a controlling subsidiary stake falls under M&A Activity.
2026-05-20 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement detailing the resolutions passed at the company’s 2025 annual shareholders’ meeting, including vote counts and percentages for each proposal. It does not present financial statements or broader report content but specifically declares voting outcomes. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (Code: DVA).
2026-05-18 Chinese
北京市金杜律师事务所上海分所关于罗欣药业集团股份有限公司2025年年度股东会之法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter (法律意见书) issued by King & Wood law firm regarding the convening, procedures, attendance, and voting results of the company’s 2025 Annual General Meeting held on May 18, 2026. It is not the AGM materials (presentation), not the formal vote results announcement by the company (which would be a pure DVA), nor does it fit other specific financial or governance report categories. It is a compliance/legal document to be filed, so it falls under the fallback “Regulatory Filings (RNS).”
2026-05-18 Chinese
关于总经理辞职暨聘任总经理的公告
Board/Management Information Classification · 90% confidence The document is a public announcement by the company’s board regarding the resignation of the current general manager and the appointment of a new general manager, including details of board deliberations, individual qualifications, and shareholdings. This fits the definition of a Board/Management Information filing (MANG).
2026-05-11 Chinese
董事会议事规则
Governance Information Classification · 93% confidence The document is the full text of the company’s “Board of Directors Rules of Procedure,” detailing governance structure, board powers, director duties, meeting procedures, committees, and internal decision-making rules. It is not an announcement of a report, nor a management change notice, nor financial statements; rather it is a governance charter. According to our classification, this falls squarely under Governance Information (CGR).
2026-05-11 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.